Tocilizumab
- PDF / 169,750 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 102 Downloads / 168 Views
1 S
Allergic reaction and lack of efficacy: 2 case reports In a study of 30 juvenile patients treated between June 2016 and October 2018 at Affiliated Children’s Hospital of the Capital Institute of Paediatrics, 2 paediatric patients [exact ages and sexes not stated] were described, who developed allergic reaction in the form of high fever, chills, rash and increase in heart rate or exhibited lack of efficacy while being treated with tocilizumab for juvenile idiopathic arthritis. The patients, who had juvenile idiopathic arthritis, were scheduled to receive tocilizumab (supplied by Shanghai Roche Pharmaceutical Co. Ltd.) every 2 weeks for 22 weeks. The patients started receiving tocilizumab [dosages and routes not stated]. Of the two patients, 1 patient developed allergic reaction in the form of high fever, chills, rash and increase in heart rate secondary to tocilizumab [duration of treatment to reaction onsets not stated]. The remaining patient exhibited a lack of efficacy to tocilizumab as no improvement in symptoms of juvenile idiopathic arthritis, including fever, rash, joint swelling and pain or laboratory parameters including WBC count, dynamic erythrocyte sedimentation rate or C-reactive protein was noted. These two patients discontinued tocilizumab. The patient, who had an allergic reaction, received unspecified anti-allergic treatment, resulting in the improvement of the symptoms. Su G, et al. The role of serum cytokine level in the evaluation of the efficacy of tocilizumab for the treatment of systemic-onset juvenile idiopathic arthritis. [Chinese]. Chinese Journal of Laboratory Medicine 43: 85-90, No. 1, 11 Jan 2020. Available from: URL: http://doi.org/10.3760/cma.j.issn.1009-9158.2020.01.010 [Chinese: summarised 803515715 from a translation]
0114-9954/20/1831-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 21 Nov 2020 No. 1831
Data Loading...
